Enalare Therapeutics Appoints Mark Coleman M.D. to Its Board of Directors

The Addition of Dr. Coleman Further Enhances the Company’s Deep Medical, Enterprise Leadership, and Capital Markets Experience

PRINCETON, N.J., January 19, 2021 - Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed Mark Coleman M.D. to its Board of Directors.  

“We are very excited to have Dr. Coleman join our team,” stated Joe Pergolizzi MD, co-founder and Chief R&D Officer of Enalare.  “Mark is a talented clinician, medical-scientist, and seasoned C-suite executive who brings many skills that complement and balance our current world-class board.” 

“I am thrilled to have Mark as a member of our board,” added Herm Cukier, Executive Chairman, President, and CEO of Enalare.  “His unique combination of experiences will be invaluable as we prepare to advance the development of our lead asset ENA-001 for the treatment of acute respiratory depression and further scale the Company as a leader in the treatment of critical care conditions.”

Mark is currently President of National Spine and Pain Centers, the nation’s largest MSO serving interventional pain management practices, a corporation with more than 1,000 employees who perform more than one million patient encounters per year.  Under Mark’s leadership, the company has leveraged its private equity funding to experience dramatic organic growth and complete several mergers and acquisitions.  Dr. Coleman is also a highly sought-after pharmaceutical and medical device company consultant and scientific advisor whose clients have included Abbott, Medtronic, and Collegium among many others.  He was an advisor early in the formation of Axsome Therapeutics (NASDAQ: AXSM) and has been a member of its board of directors since 2014.  Mark’s research experience includes winning an award of distinction from the NIH (NINDS) for his work on the pharmacologic manipulation of nerve transmission.  He is a graduate of Wesleyan University and received his medical degree from Johns Hopkins University School of Medicine.  Dr. Coleman is also a Diplomat of the American Board of Anesthesiology.

“I am both honored and delighted to join the board of directors of Enalare,” said Dr. Coleman.  “ENA-001 is an exciting new product candidate with a unique therapeutic profile. I look forward to dedicating my efforts to assist the Enalare team in bringing this needed compound to patients in the drug overdose, perioperative, and critical care settings.”

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions including respiratory depression caused by drug overdose, post-surgery, and COVID-19.  The Company is planning to initiate pivotal studies in the US for its lead compound ENA-001 in the near term.

###

Contact:

Morgan Wagner

Investor Relations

mwagner@enalare.com